Abortive infection in HeLaCD4 cells by a primary HIV type 1 isolate: implications for differential host cell tropism.
The emergence of T cell-tropic, syncytium-inducing (T-tropic/SI) HIV-1 variants from the background of macrophage-tropic, non-syncytium-inducing (M-tropic/NSI) strains is associated with disease progression in infected individuals. HIV89.6 is a primary isolate with a transitional phenotype: like M-tropic strains it replicates in primary macrophages and lymphocytes but not in most transformed cells, yet it is also syncytium inducing. We have shown that HIV89.6 can utilize both the M-tropic and T-tropic cofactors CCR-5 and CXCR-4, respectively, in conjunction with CD4 for fusion and entry into otherwise nonpermissive nonhuman cells. To better understand the nature of restricted HIV89.6 infection of transformed cells, we analyzed its interaction with CD4-expressing transformed human HeLaCD4-LTR/beta-Gal cells, which contain the beta-galactosidase gene linked to the HIV-1 LTR. Here we show that HIV89.6 enters these cells and undergoes reverse transcription and integration. Furthermore, HIV89.6 induces LTR-driven beta-galactosidase expression, indicating Tat-dependent trans-activation, in a similar number of cells as the permissive T-tropic/SI isolate HIV(HXB). Acute infection with HIV89.6, however, produces markedly lower levels of p24 antigen and infectious virus per trans-activation-positive cell than HIV(HXB). In contrast, transfection results in high levels of expression for both viruses but HIV89.6 still fails to establish spreading infection. HIV89.6 is also blocked after entry in two other nonpermissive cell lines, SUP-T1 and U937. HIV89.6 arrest in HeLaCD4-LTR/beta-Gal cells at a stage subsequent to entry, reverse transcription, integration, and Tat expression is a novel level at which HIV-1 strain- and cell-specific restrictions define host cell tropism. These studies emphasize that complex patterns of tropism are determined by the interplay of permissive or restricted virus-cell interactions at multiple steps in the replication cycle.
Smyth
R J
RJ
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Yi
Y
Y
Kim
F M
FM
Collman
R G
RG
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000096:biosynthesis / Q000502:physiology*; D015704:CD4 Antigens / Q000096:biosynthesis / Q000502:physiology*; D002459:Cell Fusion; D002460:Cell Line; D004279:DNA, Viral / Q000032:analysis / Q000096:biosynthesis; D016655:HIV Core Protein p24 / Q000096:biosynthesis; D016325:HIV Long Terminal Repeat / Q000187:drug effects; D015497:HIV-1 / Q000302:isolation & purification / Q000472:pathogenicity / Q000502:physiology*; D006367:HeLa Cells; D006801:Humans; D007700:Kinetics; D016133:Polymerase Chain Reaction; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D015533:Transcriptional Activation; D014162:Transfection; D016662:Virus Integration; D014779:Virus Replication; D015215:Zidovudine / Q000494:pharmacology; D001616:beta-Galactosidase / Q000096:biosynthesis
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015704:CD4 Antigens; D004279:DNA, Viral; D016655:HIV Core Protein p24; D011993:Recombinant Fusion Proteins; D015215:Zidovudine; D001616:beta-Galactosidase